A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ChemoCentryx

Criteria

Key Inclusion Criteria:

• moderate to severe Crohn's Disease

• CDAI 250-450

• CRP >7.5

• signed written informed consent

Key Exclusion Criteria:

• > 100 cm of small bowel resected

• ileostomy, colostomy or rectal pouch

• diagnosis of ulcerative colitis or indeterminate colitis

• evidence of short bowel syndrome requiring enteral or parenteral supplementation or total parenteral nutrition

• hepatitis B, C or HIV infection

• history of infection requiring IV antibiotics

• serious or GI infection in the previous 12 weeks